Abstract medical visualization of brain neural networks with amyloid plaques and hyperbaric oxygen therapy concept

New Mouse Study Suggests HBOT May Slow Alzheimer’s Pathology — But FDA Has Not Approved It

Experimental Neurology published findings in February 2026 that add to a growing, if cautious, body of literature on hyperbaric oxygen therapy (HBOT) and neurodegenerative disease. Researchers from Lanzhou University Second Hospital and Shenzhen People’s Hospital report that HBOT reduced amyloid-β plaque burden, restored mitochondrial quality control, and improved cognitive performance in 5xFAD transgenic mice — a widely used model of familial Alzheimer’s disease.

The study arrives at a moment of renewed interest in non-pharmacological interventions for dementia, yet it also underscores a persistent gap between preclinical promise and regulatory approval.

What the Researchers Found

The Chinese team, led by Min Yao and Zhaoming Ge, subjected 5xFAD mice to a 60-day HBOT protocol and observed several measurable improvements. Longitudinal PET-MR imaging with the amyloid tracer 18F-AV-45 revealed progressively reduced tracer uptake, suggesting diminished plaque accumulation. Histological analysis confirmed reduced plaque burden and upregulation of LRP1, a transporter involved in amyloid clearance.

Behavioral testing offered complementary evidence. Treated mice demonstrated improved spatial memory in Y-maze tests and spent more time in the center of open-field arenas — behaviors interpreted as reduced anxiety-like responses and enhanced exploratory confidence.

Mechanistically, the authors point to restored mitophagy — the cellular process that clears damaged mitochondria. HBOT upregulated PINK1 and parkin expression, enhanced autophagosome formation, and shifted microglia toward a surveillance phenotype characterized by smaller soma and increased branching. Reduced neuroinflammation, measured by IL-1β levels, accompanied these changes.

The authors conclude that HBOT’s ability to act on “multiple pathological cascades” — amyloid clearance, mitochondrial quality control, synaptic maintenance, and neuroinflammation — makes it a “uniquely promising therapeutic strategy,” particularly if initiated at early disease stages.

From Mice to Humans: What the Clinical Evidence Shows

Animal models, however well-designed, do not guarantee human efficacy. A systematic review and meta-analysis published in Frontiers in Aging Neuroscience in March 2024 attempted to bridge this gap by pooling data from 11 randomized controlled trials (RCTs) involving 847 participants with Alzheimer’s disease.

The analysis, conducted by researchers at Fujian Medical University, found statistically significant improvements in several standardized cognitive assessments. Patients receiving HBOT showed mean increases of 3.08 points on the Mini-Mental State Examination (MMSE) and decreases of 4.53 points on the Alzheimer’s Disease Assessment Scale-Cognitive (ADAS-Cog) — changes that, while modest, exceeded those in control groups. Activities of daily living scores also improved, and the intervention appeared safe, with no significant difference in adverse events between groups.

Yet the authors cautioned that methodological limitations pervaded the literature. All 11 trials were conducted in China, raising questions about generalizability. Most lacked blinding, and heterogeneity was substantial for several outcomes. The Cochrane risk-of-bias assessment identified high risk in the blinding domain across all included studies.

The FDA Position: Not Approved for Alzheimer’s

Despite accumulating research, the U.S. Food and Drug Administration has not cleared HBOT for Alzheimer’s disease, dementia, or any neurodegenerative condition outside the approved indications. In its August 2025 Letter to Health Care Providers, the agency reminded clinicians that HBOT devices are Class II medical devices cleared through the 510(k) process for specific conditions — decompression sickness, carbon monoxide poisoning, certain non-healing wounds, and others — but not for the expanding list of off-label uses promoted in wellness and longevity markets.

“Hyperbaric devices are not proven to cure cancer, Lyme disease, autism, or Alzheimer’s disease,” the FDA has stated in consumer communications, “and are not approved by the FDA to treat those ailments.” Harvard Health Publishing echoed this position in December 2024, noting that “the scientific evidence supporting these uses is thin to nonexistent” and warning that some treatment centers market HBOT for conditions beyond its established indications.

The FDA’s 2025 safety communication also highlighted emerging concerns about device-related fires and serious injuries, emphasizing the importance of proper training, grounding, and adherence to manufacturer protocols — particularly as HBOT availability expands beyond hospital-based programs into outpatient and wellness settings.

Ongoing Research and the Path Forward

Several clinical trials registered on ClinicalTrials.gov are actively investigating HBOT in cognitive impairment. One ongoing study (NCT05349318) is examining HBOT for prodromal Alzheimer’s disease with cerebrovascular disease, while others are exploring applications in post-stroke recovery, long COVID-related cognitive symptoms, and traumatic brain injury.

The Experimental Neurology authors themselves acknowledge the translational distance between their murine findings and clinical practice. “These studies will be critical in establishing the clinical applicability of HBOT in the treatment of Alzheimer’s disease,” they write, implicitly recognizing that rodent results require validation in rigorously designed human trials — ideally multi-center, double-blind, and sham-controlled.

What Patients and Families Should Know

For individuals facing Alzheimer’s disease — patients, caregivers, and families navigating an often-devastating diagnostic landscape — the appeal of a non-invasive intervention with a favorable safety profile is understandable. HBOT is generally well-tolerated when administered in accredited medical facilities, and the 2024 meta-analysis reported no excess adverse events in treated patients.

However, the evidence remains preliminary. The FDA has not approved HBOT for dementia, insurance does not cover it for this indication, and the quality of existing clinical trials is mixed. Patients considering HBOT for Alzheimer’s should discuss the decision with their neurologist or primary care physician, understand the out-of-pocket costs, and seek treatment only at facilities that follow UHMS accreditation standards and FDA safety guidelines.

The February 2026 mouse study adds a data point to an evolving scientific conversation. Whether that conversation eventually produces an FDA-approved indication for Alzheimer’s remains an open question — one that will be answered not by preclinical models alone, but by the rigorous clinical trials now underway.

HBOToday Editorial provides evidence-based reporting on hyperbaric oxygen therapy research, regulation, and clinical practice. We are not a medical authority; consult qualified healthcare providers for treatment decisions.

Sources

← Back to blog

New Mouse Study Suggests HBOT May Slow Alzheimer's Pathology — But FDA Has Not Approved It